Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide

    Mazdutide vs Tirzepatide

    Side-by-side comparison of Mazdutide and Tirzepatide: mechanism, half-life, dose range, safety profile, and vendor pricing.

    Mazdutide: no price on file
    Tirzepatide from $49.00

    Price snapshot

    Mazdutide

    Current low
    —
     
    7-day low
    —
    not enough history yet
    30-day low
    —
    not enough history yet
    30-day change
    —
    not enough history yet

    Tirzepatide

    Current low
    $49.00
    current listings
    7-day low
    —
    not enough history yet
    30-day low
    —
    not enough history yet
    30-day change
    —
    not enough history yet

    Mazdutide

    Mazdutide (also known as IBI362, Lilly compound LY3305677) is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist originally discovered by Eli Lilly and exclusively licensed to Innovent Biologics in 2019…

    No vendor price on file.

    Full Mazdutide profile

    Tirzepatide

    Featured

    Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid…

    Lowest listed price: $49.00 across 14 listings

    Full Tirzepatide profile

    Side-by-side comparison

    Attribute Mazdutide Tirzepatide
    Category Weight Loss Metabolic & Weight Loss
    Research Stage Approved (China, NMPA 2025); investigational in US/EU FDA Approved
    Mechanism of Action Mazdutide engages two distinct receptor systems through a single peptide molecule, each contributing to metabolic effects. GLP-1 Receptor Agonism: Similar to semaglutide and liraglutide. GLP-1 binds to GLP-1 receptor (GLP1R), a Gαs-coupled G-protein-coupled… Dual GLP-1 and GIP Receptor Agonism Tirzepatide simultaneously activates two incretin receptors: the GLP-1 receptor and the GIP receptor. While the GLP-1 receptor component provides the well-established effects of GLP-1 agonism (glucose-dependent insulin…
    Half-Life — ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification
    Typical Dose Range Research doses — clinical trial protocols vary 2500 mcg (2.5 mg) starting dose, titrated every 4 weeks through 5000, 7500, 10000, 12500, to 15000 mcg (15 mg) maximum weekly dose
    Dosing Frequency — Once weekly subcutaneous injection
    Administration — Subcutaneous (weekly)
    Side Effects Mazdutide's side-effect profile is dominated by gastrointestinal effects similar to GLP-1 agonists, with some dual-mechanism-specific considerations from the glucagon component. Most Common Side Effects: Gastrointestinal (dose-dependent): - Nausea: 40-55% at… Mild to moderate nausea (especially at initiation), headache, fatigue, constipation or diarrhea, abdominal distension. Injection site reactions. Rare: hypoglycemia, increased heart rate, pancreatitis.
    Molecular Weight 4563.14 g/mol 4813.5 Da
    Common Vial Sizes — 5mg, 10mg, 15mg

    Price History

    3 data points
    • BM
    • Half Nattys
    • Ion Peptide

    Mazdutide: potential benefits

    • Enhanced weight loss efficacy
    • Improved metabolic markers
    • Superior glucose control
    • Reduced cardiovascular risk factors

    Tirzepatide: potential benefits

    • Mean body weight reduction of 22.5% at 72 weeks - highest of any anti-obesity medication (PMID: 35658024)
    • 36.2% of participants achieved greater than or equal to 25% body weight loss (PMID: 35658024)
    • Significant HbA1c reduction in type 2 diabetes (up to 2.4% at 40 weeks in the SURPASS-5 add-on-to-insulin trial) (PMID: 35133415)
    • Potentially superior lean mass preservation versus GLP-1-only agents due to GIP component
    • Dual incretin mechanism providing complementary metabolic benefits
    • Improved lipid profiles including triglycerides, LDL cholesterol, and HDL cholesterol
    • Reduction in waist circumference and markers of visceral adiposity (PMID: 37840095)
    In-depth comparison

    Mazdutide vs Tirzepatide: the long answer

    Mazdutide is Innovent Biologics' GLP-1 + glucagon dual agonist (no GIP component); GLORY-1 Phase 3 (NEJM 2025, 610 Chinese adults) showed 12.55% mean body-weight loss at 6 mg weekly over 32 weeks and 14.01% over 48 weeks. Tirzepatide is the FDA-approved GLP-1 + GIP dual (Mounjaro/Zepbound); SURMOUNT-1 hit 22.5% at 15 mg weekly over 72 weeks. Tirzepatide wins on raw efficacy + 4-year US safety record; mazdutide's case is shorter titration + cheaper research-use channels + glucagon-driven liver-fat clearance.

    Last reviewed: May 19, 2026

    Mechanism: different second receptor, different downstream effects

    Both are weekly subQ injectable peptides, both target GLP-1 (slows gastric emptying, suppresses appetite, amplifies insulin secretion). The difference is the second receptor each one hits. Tirzepatide adds GIP: glucose-dependent insulinotropic polypeptide, which potentiates GLP-1 and has some direct adipose effects. Mazdutide adds glucagon receptor agonism, which drives hepatic lipolysis (liver fat clearance) and can raise energy expenditure (shown in animal models and in short human glucagon studies, not yet published for mazdutide itself). Practically: tirzepatide hits two appetite + insulin levers; mazdutide hits one appetite/insulin lever + one metabolic-rate/liver-fat lever. The mechanistic profile makes mazdutide more interesting for users with significant fatty liver (NAFLD/MASLD), though in the 48-week GLORY-1 trial it raised heart rate by about as much as GLP-1 receptor mono-agonists do.

    • Tirzepatide: GLP-1 + GIP dual agonist (Eli Lilly)
    • Mazdutide: GLP-1 + glucagon dual agonist (Innovent Biologics / Eli Lilly partnership)
    • Glucagon effect: Drives hepatic lipid clearance and can raise energy expenditure (animal models and short human glucagon studies). Neither GIP nor pure GLP-1 has this

    Efficacy: GLORY-1 vs SURMOUNT-1

    Tirzepatide's SURMOUNT-1 (NEJM 2022, 2,539 adults) showed 22.5% mean body-weight loss at 15 mg over 72 weeks. Mazdutide's GLORY-1 (NEJM 2025, 610 Chinese adults with overweight or obesity) showed 12.55% at 6 mg over 32 weeks and 14.01% at 48 weeks, so weight was still coming down after week 32, and a second Phase 3, GLORY-2, took the dose to 9 mg and reported 16.65% over 60 weeks (JAMA 2026). Cross-trial efficacy comparison is muddy because of population differences (Chinese vs Western), trial duration and different estimands, so the honest read is the two sets of figures side by side rather than one gap number. Mazdutide's edge: faster titration (8-week target vs 16-week for tirzepatide) means earlier weight-loss visibility.

    • Tirzepatide @ 15 mg (72 wk): 22.5% mean body-weight loss (SURMOUNT-1)
    • Mazdutide @ 6 mg (32 wk): 12.55% mean body-weight loss (GLORY-1), 14.01% at 48 weeks
    • GLORY-2 at 9 mg: 16.65% at 60 weeks in Chinese adults with obesity

    Dosing: both titrate, mazdutide gets there faster

    Tirzepatide standard titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg subQ weekly, +1 step every 4 weeks. Full titration to maintenance dose takes 20 weeks. Mazdutide titration per DREAMS protocol: 1.5 → 3 → 4.5 → 6 mg weekly, +1 step every 2 weeks. Full titration in 8 weeks. The faster ramp is a double-edged sword: earlier weight loss but more concentrated GI side-effect exposure. Reconstitution is identical (BAC water, subQ abdomen/thigh/upper arm, refrigerate). Mazdutide research-use vials run $0.50-1.50/mg in the gray market; tirzepatide research-use ran $0.30-0.60/mg before FDA enforcement reduced supply.

    • Tirzepatide titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, +1 step every 4 weeks (20 weeks total)
    • Mazdutide titration: 1.5 → 3 → 4.5 → 6 mg, +1 step every 2 weeks (8 weeks total)
    • Reconstitution: Both: BAC water, subQ once weekly; refrigerate 4-30 days

    Safety: shared GI profile, small heart-rate rises

    GI events dominate, as in the whole GLP-1 class. In GLORY-2, at the 9 mg dose, vomiting was reported by 53.1% of participants, nausea by 46.9% and diarrhea by 39.4%, mostly mild to moderate. They peak during titration and fade by week 4 of each new dose. In the 48-week GLORY-1 trial, mazdutide raised average heart rate by no more than 5 beats per minute, about as much as GLP-1 receptor mono-agonists do, and lowered blood pressure rather than raising it. Long-term cardiovascular outcomes are not yet published. Tirzepatide also raises heart rate (Zepbound's label: an average of 1 to 3 beats per minute), and its 4-year post-market data shows no novel cardiovascular concerns vs GLP-1 mono-agonists. Tirzepatide carries the boxed thyroid C-cell tumor warning (rodent finding, no confirmed human signal); mazdutide has no FDA label, since it is approved in China and not in the US.

    • Shared GI: Nausea, vomiting and diarrhea lead on both; mazdutide's rates rise with dose, to vomiting 53.1%, nausea 46.9% and diarrhea 39.4% at 9 mg in GLORY-2
    • Mazdutide-specific: In GLORY-1, average heart rate rose no more than 5 bpm and blood pressure went down, not up
    • Tirzepatide-specific: No novel CV signals vs class; 4-year post-market data clean
    • Tirzepatide boxed warning: Thyroid C-cell tumor risk, contraindicated in MEN-2 or family MTC history. Mazdutide has no FDA label.

    Cost + access: pharmacy in US vs research-use

    Tirzepatide retail in 2026: Mounjaro ~$1,000/month US pharmacy, Zepbound ~$1,200/month. Insurance broad for T2D, mixed for obesity. The compounded route mostly closed after the FDA declared the tirzepatide shortage resolved (October 2024, confirmed in December) and the grace periods ran out in February and March 2025. Mazdutide is approved in China, for weight management in June 2025 and for type 2 diabetes in September 2025, but it is not FDA-approved; a US Phase 2 trial in 179 adults with obesity or overweight published results in August 2026. Until an FDA approval, mazdutide is research-use only in the US: vials sourced via gray-market channels run $0.50-1.50/mg, putting a 6 mg/wk protocol at ~$3-9/week in raw molecule cost. For US-based users seeking pharmacy access today, tirzepatide is the only option; for research-use users prioritizing cost, mazdutide is dramatically cheaper.

    • Tirzepatide retail: $1,000-1,200/mo US pharmacy; insurance varies by indication
    • Mazdutide retail: Approved in China (June 2025 for weight management, September 2025 for type 2 diabetes); not FDA-approved, research-use only in the US
    • Research-use cost: Mazdutide ~$3-9/wk at 6mg dose; tirzepatide research-use limited supply

    Who chooses which

    If you want pharmacy-available GLP-1+ in the US today, tirzepatide is the only legal route. If you're a research-use user comparing molecules, the case for mazdutide is faster titration (visible results by week 4-6 vs week 8-12) + cheaper supply + glucagon-driven liver-fat clearance (relevant if you have fatty liver). The case for tirzepatide is the higher weight-loss figures in its own trials + 4-year post-market safety record. Users with significant NAFLD/MASLD lean mazdutide. Users prioritizing maximum weight loss + safety track record lean tirzepatide. Retatrutide (triple agonist: GLP-1 + GIP + glucagon) outperforms both on paper, and four of its Phase 3 obesity trials have reported, including TRIUMPH-1 with 28.3% average weight loss at 80 weeks on 12 mg, but it is not approved: Lilly plans to submit it to the FDA in Q1 2027.

    Frequently asked

    What's the difference between Mazdutide and Tirzepatide?

    Mazdutide is a weight loss that mazdutide engages two distinct receptor systems through a single peptide molecule, each contributing to metabolic effects. glp-1 receptor agonism: similar to semaglutide and…. Tirzepatide is a metabolic & weight loss that dual glp-1 and gip receptor agonism tirzepatide simultaneously activates two incretin receptors: the glp-1 receptor and the gip receptor. while the glp-1 receptor component…. The two differ in mechanism, half-life (not reported vs ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification), and typical dose range.

    Which has the longer half-life, Mazdutide or Tirzepatide?

    Mazdutide has a half-life of not reported. Tirzepatide has a half-life of ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.

    Can you stack Mazdutide and Tirzepatide?

    Stacking depends on mechanism overlap, safety profile, and goals. Mazdutide and Tirzepatide should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.

    Is mazdutide the same as retatrutide?

    No. Mazdutide is a dual agonist (GLP-1 + glucagon). Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). The third receptor on retatrutide adds GIP-mediated potentiation, which produces steeper weight-loss curves in trials: Phase 2 retatrutide hit 24.2% at 48 weeks vs mazdutide's 14.01% at 48 weeks in GLORY-1, on a different estimand. Both target glucagon but retatrutide is the more aggressive intervention.

    Why is mazdutide approved in China but not the US?

    Innovent Biologics is a Chinese biotech and ran its Phase 3 trials (including GLORY-1 in obesity and DREAMS-1 and DREAMS-2 in type 2 diabetes) in Chinese populations to file with the China NMPA first. Eli Lilly is co-developing the molecule, and the US work is still at Phase 2: a 179-participant US trial in adults with obesity or overweight was published in August 2026. Until FDA approval, mazdutide is research-use only in the US.

    Can mazdutide help with fatty liver?

    Likely yes, more directly than tirzepatide or semaglutide. Glucagon receptor agonism drives hepatic lipolysis. In an exploratory analysis of GLORY-1, people who started with at least 5% liver fat saw it fall by 73.2% on 6 mg at 48 weeks, against an 8.2% rise on placebo, and a head-to-head Phase 3 against semaglutide in adults with fatty liver disease (GLORY-3) is under way. Tirzepatide and semaglutide reduce liver fat secondarily via weight loss; mazdutide hits liver fat directly through the glucagon arm. For users specifically targeting NAFLD/MASLD, mazdutide and retatrutide are the more mechanistically targeted choices.

    How does mazdutide's faster titration affect side effects?

    Per DREAMS-1 data, the faster titration (+1 step every 2 weeks vs tirzepatide's 4 weeks) concentrates GI side effects into a shorter window: nausea peaks at weeks 2-4 instead of weeks 4-8. Total cumulative GI burden over the titration phase is similar, but it hits harder + faster. Practical adjustment: many research-use users on mazdutide slow the titration to +1 step every 3-4 weeks to flatten the side-effect curve. The trial protocol isn't a requirement.

    Are there cardiovascular risks with mazdutide's glucagon agonism?

    In the 48-week GLORY-1 trial, mazdutide raised average heart rate by no more than 5 beats per minute, about as much as GLP-1 receptor mono-agonists do, and lowered blood pressure rather than raising it. A long-term cardiovascular outcomes trial has not been published. Users with uncontrolled hypertension, recent MI, or significant cardiac history should consult a clinician before starting any glucagon-arm GLP-1 (mazdutide, retatrutide). For healthy users without CV comorbidities, the signal is mild and reverses after dose stabilization.

    See current vendor prices

    Listings from the vendors we track. Prices change often, so check the vendor before you buy.

    Mazdutide prices Tirzepatide prices Compare all compounds

    Before you buy Mazdutide or Tirzepatide

    Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.

    View Vendor Scorecard

    Related comparisons

    Retatrutide vs TirzepatideTirzepatide vs SemaglutideAOD-9604 vs Tirzepatide5-Amino-1MQ vs TirzepatideRetatrutide vs SemaglutideOrforglipron vs SemaglutideAOD-9604 vs Semaglutide

    Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks, and every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.